Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZE: Mitapivat in Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
2021-000211-23Phase 3Active
- Sponsor
- Agios Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alpha thalassemia and beta thalassemia comparing Mitapivat with Placebo (2 arms). Primary endpoint: Hemoglobin response. Started Jun 2021; status: active.
02
Drugs
mitapivat
03
Conditions
alpha thalassemiabeta thalassemia
Beyond the preview
Go deeper on 2021-000211-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000211-23.